EFFECT OF CHRONIC KIDNEY DISEASE ON WARFARIN USE
Warfarin is an anticoagulant that is used for the prevention of thromboembolism in various indications. The data showed that there was a relation between renal function and warfarin use. Warfarin could reduce thromboembolism and stroke in patients with non-end-stage renal disease. But the efficacy of warfarin decreased in patients with end-stage renal disease with or without renal replacement therapy. In addition, patients with renal insufficiency took risks of bleeding more than patients with normal renal function. The most bleeding occurred via the gastrointestinal tract. Therefore, patients with chronic kidney disease should be closely monitored.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):160s-98s.
Ong-Ajyooth L, Vareesangthip K, Khonputsa P, Aekplakorn W. Prevalence of chronic kidney disease in Thai adults: a national health survey. BMC Nephrol. 2009;10:35.
Bachmann K, Shapiro R, Mackiewicz J. Warfarin elimination and responsiveness in patients with renal dysfunction. J Clin Pharmacol. 1977;17(5-6):292-9.
Nathisuwan S. The use of oral anticoagulant drugs. In: Arunmanakul P, Nathisuwan S, editors. Guidelines for pharmaceutical care in patients receiving anticoagulant drugs. Bangkok: The Association of Hospital Pharmacy (Thailand); 2016. p.1-24. (in Thai)
Kumar DR, Hanlin E, Glurich I, Mazza JJ, Yale SH. Virchow's contribution to the understanding of thrombosis and cellular biology. Clin Med Res. 2010;8(3-4):168-72.
Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008;143:180-90.
Li Q, Dai B, Yao Y, Song K, Chen D, Jiang Q. Chronic kidney dysfunction can increase the risk of deep vein thrombosis after total hip and knee arthroplasty. Biomed Res Int. 2017; 2017:8260487.
Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med. 2009;15(5):408-12.
Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial. 2003;16(3):245-56.
Kooiman J, van Rein N, Spaans B, van Beers KA, Bank JR, van de Peppel WR, et al. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. PloS one. 2014;9(5):e94420.
Kleinow ME, Garwood CL, Clemente JL, Whittaker P. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm. 2011;17(7):523-30.
Szummer K, Gasparini A, Eliasson S, Ärnlöv J, Qureshi AR, Bárány P, et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc. 2017;6(3):e004925.
Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 2019;9(3): e022478.
Bonde AN, Lip GYH, Kamper AL, Hansen PR, Lamberts M, Hommel K, e al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64(23):2471-82.
Ocak G, Rookmaaker MB, Algra A, de Borst GJ, Doevendans PA, Kappelle LJ, et al. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. J Thromb Haemost. 2018;16:65-73.
Ichihara N, Ishigami T, Umemura S. Effect of impaired renal function on the maintenance dose of warfarin in Japanese patients. J Cardiol. 2015;65(3):178-84.
All articles published and information contained in this journal such as text, graphics, logos and images is copyrighted by and proprietary to the Thai Bulletin of Pharmaceutical Sciences, and may not be reproduced in whole or in part by persons, organizations, or corporations other than the Thai Bulletin of Pharmaceutical Sciences and the authors without prior written permission.